RxDoctor Payments DataLook up a doctor →

Claude Galphin

Nephrology · Chattanooga, TNNPI 1700883816

Payments from drug & device makers

$2,007,196in general payments, 2019–2025

Across 783 payments — averaging $2563.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Akebia Therapeutics Inc$1.1M
  • Vertex$226K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$190K
  • AstraZeneca$156K
  • Gilead$107K
  • CSL Behring$69K
  • plus $171K from 17 others

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Akebia Therapeutics Inc592$1,088,778
Vertex3$225,662
Otsuka Pharmaceutical Development & Commercialization, Inc.3$190,186
AstraZeneca(2 entities)15$156,463
Gilead27$106,929
CSL Behring46$68,588
Bayer18$35,215
Astrazeneca UK Limited8$34,982
Rigel Pharmaceuticals, Inc.2$26,632
AbbVie3$17,627
Alnylam Pharmaceuticals Inc.9$17,241
Boehringer Ingelheim13$15,793
Aurinia Pharma U.S., Inc.3$11,750
EMD Serono, Inc.21$10,712
Boehringer Ingelheim International GmbH6$388
Otsuka America Pharmaceutical, Inc.6$91
Vifor Pharma, Inc.2$42
Mallinckrodt Hospital Products Inc.1$30
ANI Pharmaceuticals, Inc.1$19
GSK1$19
OPKO Pharmaceuticals, LLC1$17
Shire North American Group Inc1$16
Genentech USA, Inc.1$16

How this compares

$2,007,196 in reported general payments places this provider in the 95th percentile of 229 nephrology providers in Tennessee.

See all nephrology providers in Tennessee →

Other nephrology in Chattanooga

See the full list for Tennessee →

Where these figures come from

Is this you, or does something look wrong? →